Aquestive receives $11.5M payment from Indivior, extends commercial agreement to 2026

Aquestive Therapeutics, Inc.

Amendment No. 11 extends Commercial Exploitation Agreement with Indivior to August 16, 2026, with automatic one-year renewals.
Indivior paid $11.482 million, including $5.482M for 2022 and estimated 2023 price increases.
Amendment revises transfer pricing and payment terms for supplied product.
Agreement will not auto-renew after last product patent expires; earlier termination rights remain.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. amended Amendment No. 11 with Indivior Inc. valued at $11,482,000 (effective 2023-03-02).

Action: amendment
Counterparty: Indivior Inc.
Value: $11,482,000
Effective: 2023-03-02

Exact text from the filing

Amendment No. 11 (the “Amendment”) to the Commercial Exploitation Agreement (the “Agreement’), dated as of August 15, 2008, with Indivior Inc.

View on SEC.gov

Browse all material agreements →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-006560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.